Phase 2 FLT3-ITD Clinical Trials

2 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 1–2 of 2 trials

Recruiting

Phase 2

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

AML, AdultRefractory AMLRelapsed Adult AML+2 more

French Innovative Leukemia Organisation33 enrolled20 locationsNCT06022003

Completed

Phase 2

Investigating the role of targeted therapy Sorafenib - the Fms-like tyrosine kinase 3 (FLT3) inhibitor, in combination with intensive chemotherapy, for previously untreated adult patients with Acute Myeloid Leukaemia (AML) with FLT3 mutations. A Phase II randomised placebo-controlled multi-centre study

Previously untreated adult acute myeloid leukaemia (AML) with FLT3-ITD mutation.

Leukaemia Foundation of Australia102 enrolled15 locationsACTRN12611001112954